Pharmaceutical Solid dosage forms comprising 3 - (2,6 - Dichloro - 3,5 - dimethoxy phenyl) - 1 - (6 - [4 - (ethyl - piperazin-1-yl) - phenylamino] pyrimidin-4-yl) - 1 - Methyl urea or a pharmaceutically acceptable Salt thereof. Processes of preparing such Pharmaceutical Solid dosage forms.Claim 1: a Capsule for oral administration comprising (a) The Drug 3 - (2,6 - Dichloro - 3,5 - dimethoxy phenyl) - 1 - (6 - [4 - (ethyl - piperazin-1-yl) - phenylamino] pyrimidin-4-yl) - 1 - methyl - urea or a pharmaceutically acceptable Salt thereof, (b) one or more Binding, and (c) one or more d Esintegrantes.Claim 26: a Capsule for oral administration comprising any of claims 1 to 7, 19 and 25, which includes: (a) between 3 and 40% by weight of the drug 3 - (2,6 - Dichloro - 3,5 - dimethoxy phenyl) - 1 - (6 - [4 - (ethyl - piperazin - 1 - IL) - phenylamino] pyrimidin-4-yl) - 1 - Methyl urea form Free Base present as mono - phosphate Salt, (b) 0.5 and 5% by weight of hydroxypropylmethylcellulose, and (c) between 1 and 4% by weight of crosslinked polyvinylpyrrolidone, based on the total weight of the Capsule contents.Formas sólidas de dosificación farmacéutica que comprenden 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea o cualquier sal farmacéuticamente aceptable del mismo. Procesos de elaboración de dichas formas sólidas de dosificación farmacéutica. Reivindicación 1: Una cápsula para administración oral que comprende (a) el fármaco 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea o cualquier sal farmacéuticamente aceptable del mismo, (b) uno o más aglutinantes, y (c) uno o más desintegrantes. Reivindicación 26: Una cápsula para administración oral que comprende cualquiera de las reivindicaciones 1 a 7, 19 ó 25 que comprende: (a) entre 3 y 40% por peso del fármaco 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenilamino]-pirimidin-4-il}-1-m
